PPAR γ agonists inhibit angiogenesis by suppressing PKCα-and CREB-mediated COX-2 expression in the human endothelium

Cardiovascular Research

Volumn 86, Issue 2, 2010, Pages 302-310

  Scoditti, Egeria ^a,b   Massaro, Marika ^a,b   Carluccio, Maria Annunziata ^a   Distante, Alessandro ^a,c   Storelli, Carlo ^b   De Caterina, Raffaele ^a,d  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Angiogenesis; Cyclooxygenase 2; Gene expression; Growth factors; Protein kinase C

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; CARRIER PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLOOXYGENASE 2; MESSENGER RNA; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; ROSIGLITAZONE; SMALL INTERFERING RNA; VASCULOTROPIN; 2 CHLORO 5 NITROBENZANILIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 2,2-BIS(4-GLYCIDYLOXYPHENYL)PROPANE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANGIOGENESIS INHIBITOR; ANILIDE; BENZOPHENONE DERIVATIVE; CREB1 PROTEIN, HUMAN; CYCLOOXYGENASE 2 INHIBITOR; DRUG DERIVATIVE; EPOXIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRKCA PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; SULFONAMIDE; TYROSINE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; BINDING SITE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROMOTER REGION; PROTEIN TRANSPORT; RNA INTERFERENCE;

ANGIOGENESIS INHIBITORS; ANILIDES; BENZOPHENONES; BINDING SITES; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOWN-REGULATION; ENDOTHELIAL CELLS; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; NITROBENZENES; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-ALPHA; PROTEIN TRANSPORT; RNA INTERFERENCE; RNA, MESSENGER; SULFONAMIDES; TETRADECANOYLPHORBOL ACETATE; THIAZOLIDINEDIONES; TRANSFECTION; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951682622     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp400     Document Type: Article

References (41)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660. (Pubitemid 36749213)
2. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for anti-angiogenic therapy. Semin Oncol 2004;31:2-11. (Pubitemid 38879409)
3. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
4. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. Antiangio-genic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60: 1306-1311.
5. Schönbeck U, Sukkova G, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999;155:1281-1291. (Pubitemid 29488935)
6. Sennlaub F, Valamanesh F, Vazquez-Tello A, El-Asrar AM, Checchin D, Brault S et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003;108:198-204. (Pubitemid 36871303)
7. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008;102:283-294.
8. Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 2001;119: 709-717. (Pubitemid 32417377)
9. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-9121. (Pubitemid 29164719)
10. Giaginis C, Margeli A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. Expert Opin Investig Drugs 2007;16:1561-1572. (Pubitemid 350028408)
11. Carluccio MA, Massaro M, Bonfrate C, Siculella L, Maffia M, Nicolardi G et al. Oleic acid inhibits endothelial activation: a direct vascular antiatherogenic mechanism of a nutritional component in the mediterranean diet. Arterioscler Thromb Vasc Biol 1999; 19:220-228. (Pubitemid 29072733)
12. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992;99:683-690. (Pubitemid 23002027)
13. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci USA 2006;103:15184-15189. (Pubitemid 44583185)
14. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflamma-tory cytokines. J Clin Invest 1995;96:60-68.
15. Freed MI, Allen A, Jorkasky DK, DiCicco RA. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol 1999;55:53-56. (Pubitemid 29144100)
16. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985;42:469-477.
17. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274: 8328-8334. (Pubitemid 129518234)
18. Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, Meyer-Kirchrath J et al. Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 2002;105:2760-2765. (Pubitemid 34615148)
19. Hirai K, Ezumi Y, Nishida E, Uchiyama T, Takayama H. Comparative study of vanadate-and phorbol ester-induced cyclo-oxygenase-2 expression in human endothelial cells. Thromb Haemost 1999;82:1545-1552. (Pubitemid 29527653)
20. Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB. Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem 2001;276:25184-25189. (Pubitemid 37413000)
21. Wu G, Mannam AP, Wu J, Kirbis S, Shie JL, Chen C et al. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol 2003;285:H2420-H2429. (Pubitemid 37443058)
22. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A et al. Effect of rosiglita-zone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 2006;26: 845-850. (Pubitemid 43732161)
23. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008;57:1394-1404.
24. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ et al. PPAR-gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-932.
25. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 2005;39:443-452.
26. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-429. (Pubitemid 32298544)
27. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001;286:923-928. (Pubitemid 32924860)
28. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52. (Pubitemid 32095641)
29. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002;68-69:95-114. (Pubitemid 35247390)
30. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 2005;102:4459-4464. (Pubitemid 40397134)
31. Han S, Ritzenthaler JD, Rivera HN, Roman J. Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol 2005;289:L419-L428. (Pubitemid 41192717)
32. Sharma C, Pradeep A, Pestell RG, Rana B. Peroxisome proliferator- activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J Biol Chem 2004;279:16927-16938. (Pubitemid 38560445)
33. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its iso-forms, and endothelial cell growth. J Clin Invest 1996;98:2018-2026. (Pubitemid 26376289)
34. Xu H, Czerwinski P, Hortmann M, Sohn HY, Forstermann U, Li H. Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc Res 2008;78:349-355. (Pubitemid 351556090)
35. Verrier E, Wang L, Wadham C, Albanese N, Hahn C, Gamble JR et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 2004;94:1515-1522. (Pubitemid 38780325)
36. von Knethen A, Soller M, Tzieply N, Weigert A, Johann AM, Jennewein C et al. PPAR-gamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J Cell Biol 2007;176:681-694. (Pubitemid 46333982)
37. Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M et al. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells. J Biol Chem 2001;276:47650-47657. (Pubitemid 37373152)
38. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289. (Pubitemid 41416583)
39. Rosen CJ. The rosiglitazone story\lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844-846. (Pubitemid 47347317)
40. Ichiki T. Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both? Arterioscler Thromb Vasc Biol 2006;26:449-455.
41. Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, Chun GT et al. The PKA/CREB pathway is closely involved in VEGF expression in mouse macrophages. Mol Cells 2007;23:23-29.